Deals & IPOs

PharmaLogic Buys Lantheus CDMO Business and Springfield Plant

PharmaLogic will acquire Lantheus' CDMO business and Springfield, NJ plant, gaining U.S. radiopharmaceutical capacity plus a long-term deal to make lutetium Lu 177 dotatate for Lantheus. Terms undisclosed.

By Olivia Hart

3 min read

PharmaLogic: Lantheus CDMO Acquisition Expands Radiopharmaceutical Manufacturing Capacity In New Jersey
PharmaLogic: Lantheus CDMO Acquisition Expands Radiopharmaceutical Manufacturing Capacity In New Jerseyjarmoluk / pixabay

What's News

  • PharmaLogic agreed to acquire Lantheus' CDMO business and its Springfield, New Jersey manufacturing facility; financial terms were not disclosed.
  • A long-term supply agreement will have Agilera manufacture lutetium Lu 177 dotatate for Lantheus.
  • PharmaLogic operates more than 45 facilities across the U.S., Puerto Rico, Canada, and Norway.
  • Agilera has over 15 years of radioligand therapy experience and supplies an alpha-emitting therapeutic to more than 30 countries.
  • The deal awaits regulatory reviews and customary closing conditions; no closing date was given.

PharmaLogic Holdings has agreed to acquire Lantheus' contract development and manufacturing business, including its Springfield, New Jersey facility, in a deal that hands PharmaLogic a ready-made U.S. radiopharmaceutical plant rather than years of greenfield construction. Financial terms were not disclosed. The transaction also locks in a long-term supply arrangement under which PharmaLogic's therapeutic CDMO arm, Agilera, will manufacture lutetium Lu 177 dotatate for Lantheus.

The buyer already runs more than 45 facilities across the United States, Puerto Rico, Canada, and Norway. The Springfield site will fold into Agilera, and the facility's employees will join that organization. Agilera brings more than 15 years of experience supporting development and commercial introduction of radioligand therapies, and it currently supplies an alpha-emitting therapeutic product to more than 30 countries.

What does the deal change for each side?

For PharmaLogic, the acquisition extends Agilera's manufacturing presence into the United States and, in the company's view, creates a differentiated transatlantic platform for therapeutic radiopharmaceutical contract development and manufacturing. PharmaLogic intends to support customers across the product lifecycle, from early clinical research through commercial launch and international supply. The promise is broad; the source does not disclose the price, revenue of the acquired business, or capacity figures for Springfield.

For Lantheus, the transaction transfers ownership of the plant to a specialist in radiopharmaceutical contract manufacturing while preserving access to production through the supply agreement. The site has capabilities in theranostic products, which pair targeted diagnostic imaging with therapeutic applications.

What did the executives say?

"This acquisition strengthens Agilera's unique capabilities in radioligand therapies and expands our capacity in the U.S. We are proud to welcome the talented Springfield team, who will help us scale our operations to meet growing demand from our partners and the patients they serve," said Etienne Montagut, President and CEO of PharmaLogic.

Mary Anne Heino, Executive Chairperson and CEO of Lantheus, framed the sale as continuity rather than retreat: "We have a long-standing relationship with PharmaLogic, which has been an important manufacturing partner for our PET products. With its proven radiopharmaceutical expertise and manufacturing capabilities, PharmaLogic is the right long-term owner for the CDMO business and Springfield facility, with the capabilities to build on this foundation while supporting reliable supply of our newly approved radiotherapeutic for patients and healthcare providers."

Notably, Heino's reference to a "newly approved radiotherapeutic" points to the lutetium Lu 177 dotatate supply agreement as the commercial glue holding the deal together.

Why does specialized capacity matter here?

Radiopharmaceuticals use radioactive materials in diagnostic or therapeutic products. Their development and manufacturing demand specialized facilities, technical expertise, quality controls, and distribution capabilities. Production timing, handling of radioactive material, specialized transportation, and strict regulatory requirements add further constraints — conditions that favor manufacturing partners with established technical and regulatory track records.

That scarcity of qualified capacity is PharmaLogic's stated thesis: the combination of U.S. manufacturing capacity with its existing international operations positions it to serve companies developing radioligand therapies that need both technical development and commercial manufacturing. The company's broader business spans diagnostics in oncology, cardiology, and neurology, plus therapeutic production for customers seeking specialized capabilities.

What happens next?

The transaction remains subject to applicable regulatory reviews and customary closing requirements. Until completion, PharmaLogic and Lantheus will continue operating independently. Neither company stated an expected closing date.

Advisory roles were split on both sides: Leerink Partners served as financial advisor to PharmaLogic, with Goodwin as legal counsel; Solomon Partners advised Lantheus, with Covington & Burling providing legal advice.

The companies have collaborated before — PharmaLogic has provided manufacturing support for Lantheus' PET diagnostic products — and that history is expected to smooth the transition. Whether the transatlantic platform delivers on its promise will show in closed deals and shipped doses, not announcements.

Source: pulse2.com

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Staff writer covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.

2,305 articles

Related articles

« Previous articleNext article »